We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California drugmaker Medivation is acquiring the worldwide rights to BioMarin’s breast cancer drug talazoparib, in a move aimed at diversifying and expanding its global oncology footprint. Read More
The FDA and European Medicines Agency have accepted new drug applications for Boehringer Ingelheim’s Gilotrif as a treatment option for patients with advanced squamous cell lung cancer that has progressed after treatment with first-line chemotherapy. Read More
Seattle Genetics received a six-observation Form 483 from the FDA for documentation and adverse event reporting failures related to its only approved product — cancer drug Adcetris. Read More
The FDA appears to have anticipated one issue drugmakers raised at a Monday public meeting on its quality metrics draft guidance — extending the comment period on the document until Nov. 27. Read More
The agency wants to improve nomenclature following complaints by generic drug and excipient makers that the current format delays ANDA filings. Read More
Industry questioned whether the FDA has the legal authority to enforce its quality metrics guidance during a Monday public meeting on the draft document. Read More
Novartis scored its second FDA approval for Promacta since acquiring the drug from GlaxoSmithKline in March, this time to treat children ages 1 to 5 with a rare blood disorder that causes low platelet counts. Read More